News

Study suggests statins could help fight gum disease

Cholesterol drug affects immune cells that drive periodontal inflammation
Anne Frances Johnson
March 25, 2024

Could taking statins benefit your mouth in addition to your arteries? A new study conducted in cell cultures showed that cholesterol-lowering drugs help to dampen the inflammation associated with periodontal disease by altering the behavior of macrophages, a type of immune cell.

Statins are the most common type of prescription medication in the United States today, taken by over 40 million Americans to lower cholesterol. The study suggests these drugs improve gum health and reduce the risk of heart disease.

Research presented at Discover BMB in San Antonio showed that statins help lower inflammation associated with periodontal disease by changing how certain immune cells behave.
Research presented at Discover BMB in San Antonio showed that statins help lower inflammation associated with periodontal disease by changing how immune cells behave.

Subramanya Pandruvada, an assistant professor in the College of Dental Medicine at the Medical University of South Carolina, oversaw the work.

“During our study, we replicated specific conditions in periodontal disease and demonstrated that introducing statins to our in vitro model modifies macrophage response,” Pandruvada said. “This allowed us to explore how medication like statins can help us treat inflammatory conditions such as periodontal disease.”

Pandruvada will present the new research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, which is being held March 23–26 in San Antonio. The study’s lead authors are Waleed Alkakhan, a graduate dental resident in periodontology, and Nico Farrar, a dental student at the Medical University of South Carolina.

Periodontal disease occurs when the growth of bacteria in the gums causes the immune system to mount an inflammatory response, contributing to symptoms such as swelling, bleeding and bone degradation. Untreated, it can lead to tooth loss. Nearly half of adults over age 30 have some form of periodontal disease, according to the U.S. Centers for Disease Control and Prevention.

Current treatments for advanced periodontal disease include antibiotics, deep cleanings of tooth and root surfaces, and various surgical procedures. Researchers have sought new ways to calm gum disease through less invasive treatment strategies.

Some previous studies have shown that people taking statins tend to show fewer signs of periodontitis than people who do not take statins. The new study is the first to trace the biochemical pathways through which statins appear to reduce periodontal inflammation.

“Recent periodontal literature has shown the beneficial effects of statins when used with traditional periodontal therapy,” Pandruvada said. “However, our study highlights a novel approach in which statins affect macrophages specifically, which, through this mechanism, can help treat periodontal disease.”

Macrophages play an important role in helping the body fight infections; however, they can also worsen inflammation depending on the form they take at different phases of the immune response. The researchers grew macrophages and gum cells together for the study and exposed them to various conditions. They found that exposure to simvastatin, a common statin drug, suppressed the macrophage inflammatory response.

As a next step, the researchers plan to study the impacts of statins on periodontal disease in animal models, a step toward determining whether this strategy might be a safe and effective approach for future periodontal therapies.

The new findings build upon the group’s initial results, which were published last year in the journal Cells.

Subramanya Pandruvada will present this research from 4:30 to 6:30 p.m. CDT on Monday, March 25, in the exhibit hall of the Henry B. González Convention Center (Poster Board No. 148) (abstract). 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Anne Frances Johnson

Anne Frances Johnson is founder and lead science writer at Creative Science Writing based in Chapel Hill, North Carolina. 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Guiding grocery carts to shape healthy habits
Award

Guiding grocery carts to shape healthy habits

Nov. 21, 2024

Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Quantifying how proteins in microbe and host interact
Journal News

Quantifying how proteins in microbe and host interact

Nov. 20, 2024

“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.

Leading the charge for gender equity
Award

Leading the charge for gender equity

Nov. 19, 2024

Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.